⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841809 | 1.00 | — | — | |
| SCHEMBL22221765 | 1.00 | — | — | |
| SCHEMBL895887 | 1.00 | — | — | |
| SCHEMBL18611199 | 1.00 | — | — | |
| SCHEMBL43806 | 1.00 | — | — | |
| SCHEMBL895888 | 1.00 | — | — | |
| SCHEMBL895537 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL20574416 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20574418 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2859458 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | claimed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | claimed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | claimed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2023250316-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023156599-A1 | SYNTHESIS OF BRUTON'S TYROSINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-24 | — | — | WO | disclosed |
| US-11701354-B2 | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090042851-A1 | SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| US-20090042851-A1 | SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| US-7456194-B2 | Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2006111549-A1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |